Erythrocin (Erythromycin Lactobionate) Patent Expiration, LOE Window & CMS Spending

Erythrocin (Erythromycin Lactobionate) by Pfizer: FDA Approved Brand (No Listed Patent), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN050609 (NDA)
Exclusivity / Cliff HorizonFDA Approved Brand (No Listed Patent)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 117.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.